Difference between revisions of "Team:NCTU Formosa/Safety"

 
(54 intermediate revisions by 8 users not shown)
Line 46: Line 46:
 
     text-decoration: none;
 
     text-decoration: none;
 
}
 
}
 +
 
del {
 
del {
 
     text-decoration: line-through;
 
     text-decoration: line-through;
Line 56: Line 57:
 
}
 
}
 
.p01{
 
.p01{
background-color:#00BBFF;
+
background-color: #33CCFF;
 
position:relative;
 
position:relative;
height:75vh;
+
height:70vh;
width:98.5vw;
+
width:100%;
padding-top:0vh;
+
 
left:0vw;
 
left:0vw;
 +
opacity:0.8;
 
}
 
}
 
.p02{
 
.p02{
background-color:#FCFCDE;
+
background-color: #FCFCDE;
 
position:relative;
 
position:relative;
width:98.5vw;
+
width:100%;
height:500vh;
+
 
}
 
}
 
.background1{
 
.background1{
background-image:url("1111.png");
+
background-image:url("https://static.igem.org/mediawiki/2015/1/1b/NCTU_Formosa_Safety_logo.png");
 
background-repeat:no-repeat;
 
background-repeat:no-repeat;
position:reltive;
+
background-position:12vh 12vh;
height:75vh;
+
position:relative;
width:70vw;
+
height:70vh;
background-size:101%;
+
width:40vw;
top:-1vh;
+
background-size:65%;
left:0vw;
+
top:0vh;
opacity:0.9;
+
left:10vw;
 +
opacity:1.0;
 
float:left;
 
float:left;
 
}
 
}
Line 85: Line 86:
 
font-size:33pt;
 
font-size:33pt;
 
position:relative;
 
position:relative;
height:20vh;
+
right:20vw;
width:20vw;
+
top:33vh;
left:-5vw;
+
top:20vh;
+
 
color:#fff;
 
color:#fff;
 
z-index:100;
 
z-index:100;
Line 94: Line 93:
 
text-align:center;
 
text-align:center;
 
}
 
}
.contentitle{
+
 
 +
 
 +
.content{
 
font-family:Arial;
 
font-family:Arial;
font-size:22pt;
+
font-size:20pt;
position:relative;
+
width:60vw;
width:50vw;
+
margin:0 auto;
 
left:20vw;
 
left:20vw;
right:25vw;
+
right:20vw;
top:20vh;
+
top:9vh;
 
color:#000;
 
color:#000;
text-align:left;
+
text-align: justify;
 +
padding-top:6vh;
 +
padding-bottom:8vh;
 +
}
 +
.goto{
 +
position:relative;
 +
padding-left:20vw;
 +
padding-top:3vh;
 +
float:left;
 
z-index:100;
 
z-index:100;
padding-bottom:5vh;
 
 
}
 
}
.content{
+
.goto a{
font-family:Calibri Light;
+
text-decoration:none;
 +
color:#000;
 +
}
 +
.goto1{
 +
position:relative;
 +
padding-left:76vw;
 +
padding-top:3vh;
 +
}
 +
.goto1 a{
 +
text-decoration:none;
 +
color:#000;
 +
}
 +
 +
p{
 +
text-indent: 40px;
 +
font-family:Arial;
 
font-size:14pt;
 
font-size:14pt;
 
position:relative;
 
position:relative;
width:60vw;
 
left:20vw;
 
right:25vw;
 
top:22vh;
 
 
color:#000;
 
color:#000;
 
text-align: justify;
 
text-align: justify;
text-indent: 40px;
+
LINE-HEIGHT:25pt;
LINE-HEIGHT:30pt;
+
}
padding-bottom:15vh;
+
h1{
 +
font-size:25pt;
 
}
 
}
 +
h2{
 +
font-size:20pt;
 +
padding-top:2vh;}
 +
.image{
 +
mragin:0 auto;
 +
width:auto;
 +
text-align:center;
 +
font-size:11pt;
 +
padding-top:50px;
 +
padding-bottom:50px;
 +
}
 +
.reference{
 +
font-size:10pt;
 +
position:relative;
 +
border-top:#999 1px solid;
 +
}
 +
</style>
  
 
 
 
 
 
 
</style>
 
 
</head>
 
</head>
 
<body>
 
<body>
Line 136: Line 166:
 
</div>
 
</div>
 
<div class="p02">
 
<div class="p02">
<div class="contentitle">
 
Single chain variable fragment as probe
 
</div>
 
 
 
<div class="content">
 
<div class="content">
     Single chain variable fragment (scFv) Abs are one of the <font color=#b51c48> recombinant antibody(rAb)</font> fragments, which are popular therapeutic alternatives to full length of monoclonal Abs. Compared to generating whole Abs from animal cell culture, scFv are smaller and can be expressed rapidly, economically and in large quantities in a bacterial host, such as<font color=#b51c48> E. coli</font>. A scFv <font color=#b51c48>possesses the complete antigen binding site</font>, which contains the variable heavy (VH) and variable light domain of an antibody. The VH domain is linked to a VL domain by an introduced flexible polypeptide linker. A scFv is capable of binding its target antigens with an affinity similar to that of the parent mAb. Due to containing the specific antigen binding unit, scFv fragments show tremendous versatility and importance in<font color=#b51c48> human therapeutics and diagnostics</font>. [1] In addition, scFv fragments can be envisaged to be applied in the non-pharmaceutical sector, such as in the food, cosmetic or environmental industries. The unique and highly specific antigen-binding ability might, for example, be exploited to block specific enzymes (e.g. enzymes that cause food spoilage), bacteria (e.g. in toothpaste or mouthwashes) or to detect environmental factors present in very low concentrations (as biosensors).[2]
+
<div style="text-align:justify;">
 +
     <p>This year Apollo designed a product to mainly detect antigens. Our users include scientific researchers, clinical scientists and so on. We believe these people all have the expertise. On the other hand, our product contains <i>E. coli</i> so when applying our product, basic protective gear, lab coat and gloves, are required. Objects that come into contact with our product, for instance, tips, need to be sterilized and thrown away, in case of non-natural gene outflow. We will hand out our product to others after our safety procedure. Hence lowering the possibility of bio-contamination. </P>
 +
<br>
 +
<p>We designed a safety mechanism for our E.Cotector allowing it to be friendlier to users and to the environment. Our main objective is to <font color="#AC1F4A">maintain the fluorescence</font> but <font color="#AC1F4A">kill the bacteria</font>, which means that treated <i>E.coli</i> cannot grow in nutritious conditions such as LB.</p></div>
 +
<br><br>
  
 +
<h2>Antibiotic</h2>
 +
 +
<p> We tried antibiotics to achieve our goal. We used three kinds of antibiotics. The first one is <font color="#AC1F4A">tetracycline</font>. It can bind to 30S subunit of ribosomes and then inhibit the synthesis of proteins. The second one is  <font color="#AC1F4A">ampicillin</font>. It can inhibit the formation of the cell wall. The third one is <font color="#AC1F4A">sulfonamide (p-Aminobenzenesulfonamide)</font>. It competitively inhibits the synthesis of folate, which connects to the purine synthesis and the DNA synthesis. </p>
 +
<br><br>
 +
 +
<h2>Method and Result<br><br></h2>
 +
<p> We mixed the antibiotics and bacteria together. We used E.Cotector expressing both anti-VEGF and red fluorescence protein to do the test. After we added different concentrations of different antibiotics, we observed the <font color="#AC1F4A">fluorescence intensity</font> and the  <font color="#AC1F4A">bacterial growth</font> on LB plate every hour. We extracted 100 µL of bacterial liquid from each sample and added it to 96 well to detect the fluorescence. There will be more details on this in the <a href="https://2015.igem.org/Team:NCTU_Formosa/Protocol">protocol</a>.</p><br>
 +
<p> In the experiments, after adding tetracycline, Ampicillin, we discovered that the fluorescence <font color="#AC1F4A">remains</font> close to the <font color="#AC1F4A">original</font> value (Figure 1.) . We also used sulfonamide. However, the solubility decreased causing the concentration of sulfonamide to distribute unequally. This may be due to the fact that sulfonamide’s solubility is highly related to the solution’s pH value. The lower the pH value, the better the solubility of sulfonamide. This also means that sulfonamide creates more  <font color="#AC1F4A">damage</font> to the structure of protein, causing the fluorescence to <font color="#AC1F4A">disappear</font>. </p><br>
 +
<div class="image"><img style="margin:0 auto;width:95%;" src="https://static.igem.org/mediawiki/2015/6/66/NCTU_Formosa_safety2.png" ><br><br>
 +
Figure 1. Fluorescence of antibiotics treated E.Cotector are <font color="#AC1F4A">as large as</font> untreated E.Cotector.</div><br>
 +
 +
<p>The second step, after the addition of tetracycline, we extracted bacterial liquid from each sample and added it on to the LB plate each hour, and cultivate them at 37℃. Once there were bacterial colonies, we determined that the antibiotics did not fully kill the bacteria. Experimental results showed that when we added Ampicillin to the bacteria, bacteria could still grow on LB plate as untreated ones. On the other hand, bacteria added with Tetracycline <font color="#AC1F4A">will not grow</font> on the LB plate (Figure 2.) . </p><br>
 +
<p>According to Figure 3., we can found that the growth of our E.Cotector treated by tetracycline is inhibited (OD600 nm didn’t increase after incubated under 37℃ in the LB). On the other hand, the OD600 nm of E.Cotector not treated by tetracycline increased. As a result, we proved that the tetracycline will  <font color="#AC1F4A">inhibit the growth</font> of E.Cotector.</p>
 +
<div class="image"><img style="margin:0 auto;width:60%" src="https://static.igem.org/mediawiki/2015/a/a6/NCTU_Formosa_safety3.png" ><br><br>
 +
Figure 2.  Our E.Cotector treated by tetracycline (100µg/mL) cannot grow on the LB plate after 37℃ incubated.</div><br>
 +
<div class="image"><img style="margin:0 auto;width:95%" src="https://static.igem.org/mediawiki/2015/f/f8/NCTU_Formosa_safety1.png" ><br><br>
 +
Figure 3. The growth of E.Cotector were  <font color="#AC1F4A">inhibited</font> by tetracycline.</div><br>
 +
<p> We put the results of adding different antibiotics in Table 1. Collectively, <font color="#AC1F4A">Tetracycline performed best</font> at killing the bacteria and conserving the fluorescence. From the LB plate result, we observed that the higher the concentration of antibiotics, the less time it would take to fully kill the bacteria. In  <font color="#AC1F4A">4 hours</font> of sterilization, tetracycline (<font color="#AC1F4A">100µg/mL</font>) performed better than tetracycline (30µg/mL). Therefore, we chose tetracycline (100µg/mL) as our final safety means. </p><br>
 +
<div class="image"><img style="margin:0 auto;width:95%;" src="https://static.igem.org/mediawiki/2015/6/60/NCTU_Formosa_safety4.png" ><br><br>
 +
Table 1. Comparison of different antibiotics affected on the E.Cotector.</div><br>
 +
<p>How do we know how long it takes for tetracycline to kill all of the E.cotector? After we added tetracycline, we spread the treated bacteria on the LB plate each hour and incubated under 37℃. By counting the number of colonies, we can know the growth situation of E.Cotector. After adding tetracycline for 4 hours, there were <font color="#AC1F4A">no</font> colonies formed (Figure 4.) . So we concluded that it took <font color="#AC1F4A">4</font> hours for the tetracycline to kill the bacteria. In other words, our E.Cotector will <font color="#AC1F4A">not grow</font> anywhere after tetracycline treatment for 4 hours.</p><br>
 +
<div class="image"><img style="margin:0 auto;width:95%;" src="https://static.igem.org/mediawiki/2015/4/4a/NCTU_Formosa_safety5.png" ><br><br>
 +
Figure 4. In the beginning, tetracycline did not play a significant role. After 4 hours though, there were no colonies formed on the LB plate.</p></div><br>
 +
<p>After our E.Cotector was treated by tetracycline, we stored the bacteria in the -80℃ refrigerator, and found that the fluorescence was maintained for <font color="#AC1F4A">six days</font> (Figure 5.) . </p>
 +
<div class="image"><img style="margin:0 auto;width:95%;" src="https://static.igem.org/mediawiki/2015/a/ac/NCTU_Formosa_safety6.png" ><br><br>
 +
Figure 5. The fluorescence maintained in the -80℃ refrigerator.</div><br>
 +
</div>
 +
 +
 +
 +
 +
<div class="goto">
 +
<a href="https://2015.igem.org/Team:NCTU_Formosa/Project"><img src="https://static.igem.org/mediawiki/2015/3/3c/%E7%AE%AD%E9%A0%AD1.png"; width=50vw;><br><br>Back to Navigation</a>
 
</div>
 
</div>
<div class="contentitle">Properties and development of targeted drugs</div>
+
<div class="goto1">
<div class="content">
+
<a href="https://2015.igem.org/Team:NCTU_Formosa/Parts"><img src="https://static.igem.org/mediawiki/2015/c/c2/%E7%AE%AD%E9%A0%AD2.png"; width=50vw;><br><br>Go to Parts</a>
This year, we decided to utilize the scFv as probes to detect cancer markers and aid in the prescription of targeted drugs in cancer treatments.
+
Targeted drugs therapy utilize compounds that are capable of inhibiting target molecules, the cancer markers which send messages along signaling pathways in cell growth, cell division or cell death. Via specific binding to target molecules, targeted drugs show more accurate attack to cancer cells and less harmful damage to normal tissues. [1] The precision of targeting the cancer cells has enhanced the efficiency of treatment by a large margin. The targeted therapy is a major step forward for many cancers, especially advanced cancers, and physicians and researchers are now focusing on the development of targeted drugs, creating a new era of personalized cancer treatment.[3]Targeted therapy are so-called "personalized medicine" because health care professionals can use clinical test results from a patient to select a specific drug that has a higher likelihood of being effective for that particular person.<br><br>
+
According to the statistics, the usage rate of targeted drug therapy has increased within ten years. In Figure 1, in 2003, targeted drug therapy is not commonly used compared with other therapies, accounting for only 11% usage. Over one decade, it is estimated that the usage of targeted drug therapy dramatically increases to<font color=#b51c48> 46%</font>. It indicates targeted drugs therapy is a potential growing field and will become the commonly used therapy in cancer treatments in the near future.
+
 
</div>
 
</div>
<br><br>
 
<div class="contentitle">Pre-diagnosis of targeted drugs treatment</div>
 
<div class="content">
 
To create the new era of tailored targeted drugs, doctors must aim at<font color=#b51c48> appropriate target molecules </font>for patients with particular diseases. In 2014,<font color=#b51c48> the U.S. Food and Drug Administration (FDA) </font>issued a guidance to facilitate the development and review of <font color=#b51c48>diagnostics tests</font>. The diagnostics tests are the steps to identify the abnormal cancer biomarkers. Moreover, the purpose of diagnostics tests are to help medical practitioners <font color=#b51c48>determine which patients could benefit from the certain drugs</font>, conversely, those who should not receive the medication. If the treatment decisions is not optimal, it would not only cause the fatal body damage, but also lead to the waste of time, money and medical resources. FDA encourages the joint of targeted drugs therapies and precise diagnostics tests which are essential for the safe and effective use of targeted drugs.[4]
 
 
</div>
 
</div>
<div class="contentitle">The concept of combination therapy</div>
 
<div class="content">
 
Although targeted drugs treatments can lead to the dramatic regressions of solid tumors, the responses are often short-lived because resistant cancer cells arise after a period of treatment. The major strategy proposed for overcoming the resistance is <font color=#b51c48>combination therapy</font>. The clinical and preclinical researches further indicated that targeted drug therapy combined with another targeted drug therapy or other types of therapies to treat cancers simultaneously may attain greater effects than using only one therapy. With the concept of combination therapy, we can not only improve the treating effect but also reduce the occurrence of cancer cells resistance toward the targeted drugs as there are less probability that a single mutation will cause cross-resistance to both drugs.[2] </div>
 
<div class="contentitle">APPOllO E.Cotector</div>
 
<div class="content">To enhance the <font color=#b51c48>efficiency of diagnosis </font>and provide reference for<font color=#b51c48> proper usage of targeted drugs</font> and <font color=#b51c48>combination therapy</font>, we come up with the idea of detecting multimarker at the same time and this was how our marvelous E.Cotector is borned. This year, NCTU_Formosa commits to creating a multimarker diagnosis platform via scFv as probes for helping physicians to determine and prescribe the usage of targeted drugs in cancer patients, especially the monoclonal-antibody-targeted drugs.</div>
 
</div>
 
 
</body>
 
</body>
 
</html>
 
</html>
 
{{Team:NCTU_Formosa/footer}}
 
{{Team:NCTU_Formosa/footer}}

Latest revision as of 03:55, 19 September 2015

Safety

This year Apollo designed a product to mainly detect antigens. Our users include scientific researchers, clinical scientists and so on. We believe these people all have the expertise. On the other hand, our product contains E. coli so when applying our product, basic protective gear, lab coat and gloves, are required. Objects that come into contact with our product, for instance, tips, need to be sterilized and thrown away, in case of non-natural gene outflow. We will hand out our product to others after our safety procedure. Hence lowering the possibility of bio-contamination.


We designed a safety mechanism for our E.Cotector allowing it to be friendlier to users and to the environment. Our main objective is to maintain the fluorescence but kill the bacteria, which means that treated E.coli cannot grow in nutritious conditions such as LB.



Antibiotic

We tried antibiotics to achieve our goal. We used three kinds of antibiotics. The first one is tetracycline. It can bind to 30S subunit of ribosomes and then inhibit the synthesis of proteins. The second one is ampicillin. It can inhibit the formation of the cell wall. The third one is sulfonamide (p-Aminobenzenesulfonamide). It competitively inhibits the synthesis of folate, which connects to the purine synthesis and the DNA synthesis.



Method and Result

We mixed the antibiotics and bacteria together. We used E.Cotector expressing both anti-VEGF and red fluorescence protein to do the test. After we added different concentrations of different antibiotics, we observed the fluorescence intensity and the bacterial growth on LB plate every hour. We extracted 100 µL of bacterial liquid from each sample and added it to 96 well to detect the fluorescence. There will be more details on this in the protocol.


In the experiments, after adding tetracycline, Ampicillin, we discovered that the fluorescence remains close to the original value (Figure 1.) . We also used sulfonamide. However, the solubility decreased causing the concentration of sulfonamide to distribute unequally. This may be due to the fact that sulfonamide’s solubility is highly related to the solution’s pH value. The lower the pH value, the better the solubility of sulfonamide. This also means that sulfonamide creates more damage to the structure of protein, causing the fluorescence to disappear.




Figure 1. Fluorescence of antibiotics treated E.Cotector are as large as untreated E.Cotector.

The second step, after the addition of tetracycline, we extracted bacterial liquid from each sample and added it on to the LB plate each hour, and cultivate them at 37℃. Once there were bacterial colonies, we determined that the antibiotics did not fully kill the bacteria. Experimental results showed that when we added Ampicillin to the bacteria, bacteria could still grow on LB plate as untreated ones. On the other hand, bacteria added with Tetracycline will not grow on the LB plate (Figure 2.) .


According to Figure 3., we can found that the growth of our E.Cotector treated by tetracycline is inhibited (OD600 nm didn’t increase after incubated under 37℃ in the LB). On the other hand, the OD600 nm of E.Cotector not treated by tetracycline increased. As a result, we proved that the tetracycline will inhibit the growth of E.Cotector.



Figure 2. Our E.Cotector treated by tetracycline (100µg/mL) cannot grow on the LB plate after 37℃ incubated.



Figure 3. The growth of E.Cotector were inhibited by tetracycline.

We put the results of adding different antibiotics in Table 1. Collectively, Tetracycline performed best at killing the bacteria and conserving the fluorescence. From the LB plate result, we observed that the higher the concentration of antibiotics, the less time it would take to fully kill the bacteria. In 4 hours of sterilization, tetracycline (100µg/mL) performed better than tetracycline (30µg/mL). Therefore, we chose tetracycline (100µg/mL) as our final safety means.




Table 1. Comparison of different antibiotics affected on the E.Cotector.

How do we know how long it takes for tetracycline to kill all of the E.cotector? After we added tetracycline, we spread the treated bacteria on the LB plate each hour and incubated under 37℃. By counting the number of colonies, we can know the growth situation of E.Cotector. After adding tetracycline for 4 hours, there were no colonies formed (Figure 4.) . So we concluded that it took 4 hours for the tetracycline to kill the bacteria. In other words, our E.Cotector will not grow anywhere after tetracycline treatment for 4 hours.




Figure 4. In the beginning, tetracycline did not play a significant role. After 4 hours though, there were no colonies formed on the LB plate.


After our E.Cotector was treated by tetracycline, we stored the bacteria in the -80℃ refrigerator, and found that the fluorescence was maintained for six days (Figure 5.) .



Figure 5. The fluorescence maintained in the -80℃ refrigerator.